"Lipedema and Mast Cell Activation Syndrome: Understanding the Overlap"
If you have lipedema and your symptoms don't fully respond to conservative care — if you have widespread reactions to foods, fragrances, or medications, unpredictable flares, and pain that seems out of proportion to obvious triggers — mast cell activation syndrome may be part of the picture.
MCAS is a condition in which mast cells, a type of immune cell, activate too easily or excessively, releasing chemical mediators that produce systemic symptoms. It is significantly underdiagnosed. And it appears to co-occur with lipedema at rates that are not coincidental.
This article explains what MCAS is, why it overlaps with lipedema, how the two conditions interact, and what recognising the overlap means for management.
What is mast cell activation syndrome?
Mast cell activation syndrome (MCAS) is a disorder in which mast cells chronically and inappropriately release inflammatory mediators, producing a wide range of recurrent, multi-system symptoms.
Mast cells are immune cells found throughout the body — in skin, gut, connective tissue, the nervous system, and adipose tissue. Their normal role is to respond to threats: allergens, pathogens, and tissue damage. In MCAS, this response becomes dysregulated. Mast cells activate in response to triggers that should not cause a reaction — certain foods, heat, cold, scents, stress, hormonal fluctuations, or no identifiable cause at all.
When mast cells activate, they release mediators including:
- Histamine — causes vasodilation, fluid shifts, itching, flushing, and gastrointestinal symptoms
- Tryptase — a marker of mast cell activation; elevated serum tryptase is used in diagnosis
- Prostaglandins — contribute to pain, inflammation, and vascular changes
- Cytokines including TNF-α and IL-6 — drive systemic inflammation
MCAS is distinct from systemic mastocytosis (a clonal mast cell disorder) and classical allergic reactions (which involve IgE-mediated pathways). Most MCAS is non-clonal and does not show up on standard allergy testing.
Why lipedema and MCAS frequently co-occur
The overlap between lipedema and MCAS is not well-characterised in published literature yet, but several mechanisms make the co-occurrence physiologically plausible — and clinically consistent with what patients report.
Mast cells are present in lipedema tissue
Histological studies of lipedema adipose tissue consistently describe chronic immune cell infiltration. Among the immune cells found in lipedema tissue are mast cells, alongside macrophages and other inflammatory mediators (Phlebology, 2019; Lymphatic Research and Biology, 2018). In lipedema, these cells appear to be chronically activated within the adipose tissue itself — contributing to the local inflammatory environment that drives pain, fibrosis, and fluid accumulation.
This means the two conditions share common ground at the tissue level: both involve dysregulated mast cell activity, and in a person with both conditions, the result is a compounded inflammatory burden.
Connective tissue involvement
MCAS is strongly associated with connective tissue disorders, particularly hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders. Research published in the American Journal of Medical Genetics (Afrin et al., 2016) identified MCAS as a common comorbidity in hypermobile connective tissue disorder patients. Lipedema also involves abnormal connective tissue — including fibrosis and disrupted extracellular matrix — and is frequently reported alongside hEDS.
The three-way overlap of hEDS, MCAS, and dysautonomia (including POTS) is well-recognised in the clinical literature. Lipedema sits in the same connective tissue disorder cluster, which may partly explain why MCAS appears disproportionately in the lipedema population.
Hormonal overlap and triggers
Both lipedema and MCAS are influenced by estrogen. Estrogen promotes mast cell degranulation through estrogen receptors expressed on mast cells — meaning that hormonal events such as the menstrual cycle, pregnancy, perimenopause, and exogenous estrogen (e.g., oral contraceptives) can trigger MCAS symptoms. These are the same hormonal transitions that are associated with lipedema onset and progression.
A woman with both conditions will often notice that hormonal fluctuations produce a particularly pronounced and wide-ranging symptom response — not just the swelling and pain associated with lipedema, but also gastrointestinal symptoms, flushing, fatigue, brain fog, and heightened reactivity.
How MCAS amplifies lipedema symptoms
Even if MCAS is not the cause of lipedema, the presence of MCAS can significantly worsen the lipedema experience. The mechanism involves several pathways.
Histamine and adipose tissue. Histamine receptors (H1, H2, and H4) are expressed in adipose tissue. Research has shown that histamine influences fat cell behaviour, including adipogenesis (the formation of new fat cells) and lipid metabolism (American Journal of Physiology, 2014). Elevated histamine from mast cell activation may therefore directly affect adipose tissue in areas already compromised by lipedema.
Increased vascular permeability. Histamine and other mast cell mediators cause vasodilation and increased capillary permeability, driving more fluid into interstitial spaces. In lipedema, where lymphatic microvasculature is already impaired, this additional fluid burden worsens swelling, heaviness, and tissue pressure.
Amplified systemic inflammation. The cytokines released during mast cell activation — particularly TNF-α and IL-6 — are the same markers found elevated in lipedema tissue. In a person with both conditions, mast cell activation adds systemic inflammatory load on top of the local tissue inflammation that is already present.
Wider and less predictable trigger profile. Lipedema symptoms respond to specific, identifiable inputs — heat, prolonged standing, hormonal shifts, dietary choices. When MCAS is present, the trigger profile expands unpredictably to include foods, smells, medications, environmental factors, and emotional stress. This makes self-management significantly more complex and can make conservative care less consistently effective.
Recognising MCAS alongside lipedema
MCAS symptoms are wide-ranging and nonspecific, which makes recognition difficult. They are also frequently attributed to anxiety, irritable bowel syndrome, allergies, or other common conditions before the underlying mast cell disorder is identified.
The following symptom pattern, particularly when it occurs with lipedema, warrants investigation:
| Symptom domain | Common presentations |
|---|---|
| Skin | Flushing, hives, dermatographism, itching, rashes without identifiable cause |
| Gastrointestinal | Nausea, cramping, diarrhoea, bloating, reflux — often triggered by food |
| Cardiovascular | Heart palpitations, dizziness on standing, low blood pressure, poor heat tolerance |
| Neurological | Brain fog, headaches, difficulty concentrating, anxiety |
| Respiratory | Nasal congestion, throat tightness, shortness of breath |
| Musculoskeletal | Widespread pain, joint pain, fatigue |
| General reactivity | Reactions to foods, medications, fragrances, temperature changes |
The key distinguishing feature of MCAS is multi-system involvement and episodic or trigger-driven pattern. Individual symptoms are non-diagnostic; the pattern across systems is what raises suspicion.
What the research says
The specific research on MCAS in lipedema remains limited — this is an area where clinical observation is ahead of the published literature. However, the broader evidence supports several relevant findings:
Mast cells in adipose tissue inflammation. Multiple studies have confirmed that mast cells are active participants in adipose tissue inflammation, not passive bystanders. Mast cell density in adipose tissue correlates with inflammatory markers and insulin resistance (Cell Metabolism, 2009; Liu et al.). While this research was conducted primarily in obesity models, it is physiologically relevant to the inflamed adipose tissue of lipedema.
Estrogen and mast cell degranulation. Estrogen's capacity to promote mast cell activation via ERβ receptors is documented in endocrinology and immunology literature. This provides a mechanistic explanation for why both conditions track hormonal events so closely (Frontiers in Immunology, 2018).
Connective tissue disorders and MCAS prevalence. Studies evaluating patients with hypermobile Ehlers-Danlos syndrome — a connective tissue disorder with known overlap with lipedema — have found MCAS prevalence estimates ranging from 30 to 66% in this population (Afrin et al., American Journal of Medical Genetics, 2016; Cheung and Vadas, 2015). Given the connective tissue and inflammatory similarities between hEDS and lipedema, high MCAS co-occurrence in lipedema is mechanistically expected.
Histamine-lowering dietary approaches in lipedema. While not yet studied in a formal trial, there is clinical and patient-reported experience suggesting that low-histamine dietary modifications can reduce symptom burden in women with lipedema, particularly those with a reactive or fluctuating symptom profile — consistent with an MCAS component.
Diagnosis: what to expect
MCAS is underdiagnosed, partly because standard allergy testing is often normal and not all physicians are familiar with the condition. The diagnostic process typically involves:
- Clinical evaluation — a detailed symptom history across systems, looking for the multi-system pattern described above
- Serum tryptase — elevated baseline tryptase (>20 µg/L) is supportive; a spike of ≥20% + 2 ng/mL above baseline during symptoms is diagnostic
- Urine histamine metabolites (N-methylhistamine) — collected during symptomatic periods
- Prostaglandin D2 or PGD2 — another mast cell mediator that can be measured in urine
- Response to treatment — symptomatic improvement with antihistamines or mast cell stabilisers is considered part of the diagnostic criteria
If you are already under the care of a lipedema specialist, raising the possibility of MCAS directly — with a documented symptom pattern — will make the conversation more productive.
Management when both conditions are present
Managing lipedema alongside MCAS requires addressing both conditions, rather than treating only the lipedema symptoms that appear most prominently.
Antihistamines. H1 and H2 antihistamine therapy is a first-line approach for MCAS. Second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine) are typically used first; many patients with MCAS require dosing above standard allergy doses. H2 antihistamines (famotidine, ranitidine) address gastrointestinal mast cell activity. Both must be prescribed and monitored by a physician.
Mast cell stabilisers. Cromoglycate (cromolyn sodium), ketotifen, and quercetin are used to reduce mast cell degranulation. Quercetin, a natural flavonoid, is available without prescription and has mast cell-stabilising and anti-inflammatory properties — consistent with the flavonoid research cited in lipedema inflammation literature.
Low-histamine dietary modifications. A low-histamine diet reduces the exogenous histamine load and avoids foods that directly trigger mast cell degranulation (alcohol, fermented foods, aged cheeses, vinegar, certain fish). This is distinct from, and complementary to, the low-carbohydrate or anti-inflammatory dietary approaches commonly recommended for lipedema.
Trigger identification and avoidance. Because MCAS involves a wide and individual trigger profile, systematic identification of your specific triggers is central to management. This is where detailed daily tracking becomes genuinely valuable — not just tracking lipedema-relevant variables, but capturing reactivity events, dietary inputs, and environmental factors alongside symptoms.
Compression and MLD. Conservative lipedema management continues to apply. MLD may require modification if pressure and manual contact are themselves triggers for mast cell activation — some patients with MCAS find that certain massage techniques provoke reactions. This should be discussed with an MLD therapist experienced with reactive patients.
Hormonal management. Because hormonal fluctuations drive both conditions, addressing perimenopausal or menstrual cycle-related hormonal volatility — in consultation with a gynaecologist or endocrinologist — can reduce the frequency and severity of combined flares.
Tracking both conditions together
When MCAS is present alongside lipedema, the symptom picture becomes significantly more complex. Symptoms that appear to come from nowhere — sudden swelling spikes, unexpected pain, gastrointestinal disturbance — may be mast cell events that are worth capturing in context.
Tracking the following alongside standard lipedema variables supports pattern recognition across both conditions:
| Variable | Why it matters |
|---|---|
| Reactivity events (flushing, hives, GI disturbance) | Identifies MCAS activity separate from baseline lipedema |
| Food diary | Correlates high-histamine foods with symptom spikes |
| Hormonal/cycle phase | Confirms hormonal amplification of mast cell activity |
| Medications and supplements | Monitors for mast cell-activating substances (aspirin, NSAIDs, certain dyes) |
| Environmental exposures | Fragrances, cleaning products, temperature extremes |
| Sleep and stress | Cortisol-driven mast cell activation is a documented pathway |
The value of this kind of tracking is not to eliminate all possible triggers — which is not achievable — but to identify the most impactful ones, understand your personal pattern, and build a clinical record that supports diagnosis and treatment decisions.
What to do next
If the symptom profile described above resonates with your experience, the appropriate next step is to discuss MCAS with your GP or lipedema specialist. Bring a symptom log that captures the multi-system pattern — the more specific the documentation, the more productive the diagnostic conversation.
If you do not yet have a systematic way to track your lipedema symptoms and reactivity events together, Lipedema IQ provides daily logging for pain, swelling, diet, conservative care, and symptom notes — and generates a clinician-ready report that captures your full symptom history for appointments.
Understanding that MCAS may be present does not change the lipedema diagnosis or fundamentally alter conservative care. But it reframes why symptoms are more reactive, less predictable, and harder to control than pure lipedema management would suggest. That reframing — and the targeted management that follows — can make a meaningful difference to daily quality of life.
Frequently asked questions
What percentage of people with lipedema also have MCAS? No large-scale epidemiological study has established a precise figure for MCAS prevalence in lipedema specifically. However, given that MCAS prevalence is estimated at 17% in the general population (Molderings et al., 2011) and significantly higher in connective tissue disorder populations (30–66% in hEDS), and given the documented mast cell infiltration in lipedema tissue, clinical experience suggests meaningful co-occurrence. Many lipedema specialists are increasingly screening for MCAS in patients with highly reactive or treatment-resistant symptom profiles.
Can MCAS cause lipedema? MCAS does not cause lipedema. Lipedema is a structural condition involving adipose tissue that develops through hormonal and genetic mechanisms. However, MCAS can worsen lipedema symptoms significantly through histamine-mediated vascular permeability, amplified tissue inflammation, and expanded trigger sensitivity. The two conditions are distinct but interact.
How do I know if my lipedema flares are MCAS-related? MCAS-related flares tend to be broader in symptom profile — involving skin flushing, gastrointestinal symptoms, palpitations, or brain fog alongside increased swelling and pain. They may be triggered by factors that don't typically worsen lipedema alone (foods, fragrances, medications, temperature changes). If your flares include multi-system symptoms beyond the typical lipedema profile, MCAS is worth investigating.
Are NSAIDs safe to use with MCAS? NSAIDs (ibuprofen, aspirin, naproxen) are mast cell-activating substances for some people with MCAS and can trigger significant reactions. Paracetamol (acetaminophen) is generally better tolerated. If you have suspected or confirmed MCAS, discuss pain management options with your physician before using NSAIDs.
Does a low-histamine diet help lipedema? A low-histamine diet is not a standard recommendation for lipedema in the absence of MCAS. However, in patients with confirmed or suspected MCAS, reducing exogenous histamine load can decrease the frequency and severity of mast cell-driven flares — which in turn reduces the inflammatory amplification of lipedema symptoms. It is typically used as one component of MCAS management rather than as a standalone lipedema intervention.
Can compression garments trigger MCAS reactions? Pressure and temperature changes can be triggers for some people with MCAS, including reactions to compression garments (redness, itching, flushing at the compression site). If this is occurring, discuss with your MLD therapist and physician. Fabric choice, compression class, and wearing schedule may need to be adjusted. The goal is to maintain the benefits of compression while minimising mast cell provocation.
This article is for educational purposes only and does not constitute medical advice. If you suspect MCAS or have unexplained multi-system symptoms, seek evaluation from a qualified healthcare provider.
Important: Lipedema IQ is a personal health tracking tool. It is not a medical device and does not provide diagnoses, treatment recommendations, or clinical advice. Always consult a qualified healthcare professional for medical decisions.
Not sure if your symptoms are lipedema?
Take the free 5-question symptom checker — no sign-up required. See whether your symptoms match common lipedema patterns.
Take the Symptom Checker